title: The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.
abstract: A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development.
authors.affiliation: Wilshire Oncology Medical Group-US Oncology, La Verne, California 91750, USA. bestchemo@gmail.com
authors.forename: Linda
authors.initials: L
authors.lastname: Bosserman
authors.forename: Franklyn
authors.initials: F
authors.lastname: Prendergast
authors.forename: Roy
authors.initials: R
authors.lastname: Herbst
authors.forename: Martin
authors.initials: M
authors.lastname: Fleisher
authors.forename: Emery
authors.initials: E
authors.lastname: Salom
authors.forename: Steven
authors.initials: S
authors.lastname: Strickland
authors.forename: Anastasios
authors.initials: A
authors.lastname: Raptis
authors.forename: Allan
authors.initials: A
authors.lastname: Hallquist
authors.forename: Mathieu
authors.initials: M
authors.lastname: Perree
authors.forename: Swapnil
authors.initials: S
authors.lastname: Rajurkar
authors.forename: Misagh
authors.initials: M
authors.lastname: Karimi
authors.forename: Karl
authors.initials: K
authors.lastname: Rogers
authors.forename: Dirk
authors.initials: D
authors.lastname: Davidson
authors.forename: Carl
authors.initials: C
authors.lastname: Willis
authors.forename: Manuel
authors.initials: M
authors.lastname: Penalver
authors.forename: Howard
authors.initials: H
authors.lastname: Homesley
authors.forename: Matthew
authors.initials: M
authors.lastname: Burrell
authors.forename: Audrey
authors.initials: A
authors.lastname: Garrett
authors.forename: James
authors.initials: J
authors.lastname: Rutledge
authors.forename: Michael
authors.initials: M
authors.lastname: Chernick
authors.forename: Cary A
authors.initials: CA
authors.lastname: Presant
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002908:Chronic Disease; D055808:Drug Discovery / Q000379:methods; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D018922:HL-60 Cells; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents